Medications for the treatment of pulmonary arterial hypertension

PHA Canada
Aug 10, 2022
1 min read

Updated: Oct 7, 2024

PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read about their systemic review of PAH medications here.

Recent Posts

Using sotatercept off-label in children

Clinical trials for sotatercept didn't include children, so any pediatric use is off-label. This study, conducted at one children's hospital in San Diego, evaluated sotatercept in 7 pediatric patients

Phase 1 trial of treprostinil prodrug patch succeeds

A 9-participant phase 1 clinical trial used a patch to deliver a prodrug of treprostinil (a prodrug is something that is metabolized into the drug in question inside the body). Each participant wore a

Sotatercept lowers blood volume but increases exercise ability

In a study of a relatively low-risk population of pulmonary hypertension patients, researchers began to untangle sotatercept's complex effects on exercise. Sotatercept lowered blood volume to normal l

Comments